endocrine/exocrine glands
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
|
• rates of mammary epithelial cell proliferation are increased compared to controls
|
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
|
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
|
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
|
• 52% of mutants at 4 months of age show lobular hyperplasia
|
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
|
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ
|
neoplasm
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ
|
integument
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
|
• rates of mammary epithelial cell proliferation are increased compared to controls
|
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
|
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
|
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
|
• 52% of mutants at 4 months of age show lobular hyperplasia
|
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
|
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
breast cancer | DOID:1612 |
OMIM:114480 |
J:96383 |